BACKGROUND
SHetA2 has previously been identified by OSU researchers as a strong anti-cancer agent that induces apoptosis (cell death) in 8 different types of kidney cancer cells and is being developed for treatment of Polycystic Kidney Disease (PKD). SHetA2 is in the final stages of preclinical testing and since no toxicity to normal cells has been observed by National Cancer Institute (NCI) in trials with mice, rats, and dogs, clinical trials will begin on human patients in the near future.
SUMMARY
OSU researchers have identified and synthesized a major metabolite (active molecule) of SHetA2 as well as a conjugate (compound) form of the metabolite. The conjugate can be used to determine the specific proteins that promote cancer development, thus providing the type of information that is necessary to construct new compounds that will improve the anti-cancer activity of SHetA2.
POTENTIAL AREAS OF APPLICATION
MAIN ADVANTAGES
STATE OF DEVELOPMENT
Prototype is available.